Gilead Sciences, Inc.
GILD.TO
Get informed when a big investor buys or sells
+ FollowMarket Cap$262.28B
Close$
Share Statistics
| Market cap | $262.28 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.33 (2.16%) |
| Earnings per Share | $- |
| Beta | 0.83 |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Gilead Sciences, Inc.
17,000 employees
CEO: Daniel O'Day Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative med...